

Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal)

Technology appraisal guidance

Published: 12 December 2012

www.nice.org.uk/guidance/ta270

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of decitabine for acute myeloid leukaemia. This is because Janssen has confirmed that it does not intend to make an evidence submission for the appraisal. They consider that there is not enough evidence to provide an evidence submission.

Information

If NHS organisations wish to consider decitabine for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-6737-7